Paul Edwards Posted July 3, 2016 Share Posted July 3, 2016 Xofigo (radium 223) is a radioactive material that specifically targets bone metastases from prostate cancer. Xofigo (radium 223) is administered intravenously in hospital and is regarded as a medical service. This means that the application for it to be publicly funded must be made to the Medical Services Advisory Committee. The applications for new cancer drugs to be publicly funded are made to the Pharmaceutical Benefits Advisory Committee. According to Bayer, the manufacturer of Xofigo (radium 223), the policies that apply to listing on the Medical Benefits Schedule are different from the policies that apply to listing on the Pharmaceutical Benefits Scheme. April 2014 Recommendation that Xofigo be listed on the Medical Benefits Schedule. It has been more than 2 years since the Medical Services Advisory Committee recommended that Xofigo (radium 223) be listed on the Medical Benefits Schedule. Bayer disagreed with the proposed pricing arrangements that the Medical Services Advisory Committee recommended. What's happening now? Unfortunately, nothing. There appears to be a stalemate. A fellow Victorian sufferer with advanced prostate cancer has shared with me the copy of a recent letter that he has received from Bayer. Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.